Physician profile
Jay Page
NPI 1639229016
$4,357.48
in general payments reported to CMS, 2019-2025
30 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $123 · 2021: $336 · 2022: $1,614 · 2023: $466 · 2024: $277 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,628.55 | 2021-2025 | Urolift, Deknatel |
| Calyxo, INC. | $687.75 | 2021-2025 | Cvac Aspiration System |
| Bayer Healthcare Pharmaceuticals INC. | $355.19 | 2019-2025 | |
| Abbvie INC. | $227.39 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $191.91 | 2024-2025 | Adstiladrin |
| Boston Scientific Corporation | $188.94 | 2021-2025 | Lithovue, Spaceoar Vue System - 10ml |
| Agiliti Surgical, INC. | $131.01 | 2023 | Soltive |
| Sumitomo Pharma America, INC. | $124.78 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $113.08 | 2019-2025 | Erleada |
| Myovant Sciences INC. | $81.15 | 2021-2022 | |
| Endo USA, INC. | $75.30 | 2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $68.52 | 2022-2023 | Jelmyto |
| Blue Earth Diagnostics | $65.57 | 2019 | |
| Amgen INC. | $60.69 | 2019 | |
| Endo Pharmaceuticals INC. | $50.70 | 2023-2024 | Xiaflex, Aveed |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $42.70 | 2020 | |
| Pfizer INC. | $38.03 | 2019 | |
| Neotract INC. | $37.15 | 2019 | |
| Procept Biorobotics Corporation | $31.41 | 2025 | |
| Coloplast Corp | $22.37 | 2023 | Speedicath |
| Progenics Pharmaceuticals, INC. | $22.29 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $18.95 | 2020 | |
| Dendreon Pharmaceuticals LLC | $18.63 | 2022 | |
| Olympus America INC. | $18.55 | 2020 | |
| Allergan, INC. | $16.70 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $14.83 | 2025 | Imfinzi |
| Profound Medical Corp. | $13.96 | 2025 | Tulsa-Pro |
| Zyla Life Sciences, INC. | $11.38 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.